We are looking for an enthusiastic postdoc with bioinformatic or wet-lab focus, or a combination to join the Medical Epigenomics Lab at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna. The group of Christoph Bock combines experimental and computational methods for understanding epigenome regulation in cancer, stem cells, and immune diseases.
(Reference Code: PD Medical Epigenomics)
The lab combines large-scale analysis of the epigenome with stem cell biology and computational modeling, in order to better understand and treat leukemia and other diseases of the blood system. We work closely with biologists and medical researchers at the Medical University of Vienna, aiming to advance personalized medicine through epigenome sequencing and bioinformatic innovation. Specific research interests include (but are not limited to):
Epigenomics. The lab is part of the BLUEPRINT project aimed at establishing, analyzing and interpreting comprehensive epigenome maps of >100 cell types of the blood and immune system.
Bioinformatics. We develop bioinformatic methods and infrastructure for analyzing DNA methylation data in the context of epigenome-wide association studies.
Diagnostics. Using large-scale DNA methylation mapping, bioinformatic prioritization and functional characterization, we strive to develop clinically relevant biomarkers for informing cancer therapy.
The Principal Investigator
[http://christoph-bock.org/] Christoph Bock received his training in computer science and business science from the Universities of Mannheim and Heidelberg (Germany). He obtained a PhD in bioinformatics from the Max Planck Institute for Informatics, for which he was awarded an Otto Hahn Medal by the Max Planck Society. Christoph did his postdoc in epigenome research at the Broad Institute of MIT and Harvard, contributing to the Roadmap Epigenomics Project. In parallel, Christoph led a research group on computational epige-netics at the Max Planck Institute for Informatics. His recent publications include papers in Cell, Molecular Cell, Nature Biotechnol-ogy, Nature Methods, Nature Reviews Cancer, Nature Reviews Genetics, Science, Genome Research, Genome Biology, PLoS Com-putational Biology and Bioinformatics
(http://scholar.google.com/citations?user=9qSsTcIAAAAJ). Christoph also co-directs the high-throughput sequencing platform at CeMM, and he is a visiting professor at the Medical University of Vienna as well as a work package leader in the European epigenome mapping project (http://blueprint-epigenome.eu/).
The lab is driven by the ideas of all its members. If you already have a project in mind, we would like to hear from you. If not, here are a few topics for inspiration: (i) Why is leukemia a disease of the elderly? Can we identify an “epigenetic clock” that counts down toward leukemia? What is wrong with this clock in those rare cases of childhood leukemia? (ii) Can we construct a blood cancer from scratch, by inducing only epigenetic defects? Which combination of pathways provides the minimum core of an epigenetic leukemia? (iii) How can we make epigenome data useful for personalized medicine? Every physician uses Google – can we build a “Google for the epigenome”?